70 likes | 80 Views
The global narcolepsy market accounted to US$ 2,026.8 Mn in 2018 and is expected to grow at a CAGR of 9.5% during the forecast period 2019 u2013 2027, to account to US$ 4,537.9 Mn by 2027. <br><br>Get sample PDF copy: https://www.theinsightpartners.com/sample/TIPRE00003326/
E N D
Narcolepsy Market Narcolepsy Market to 2027 - Global Analysis and Forecasts by Type (Narcolepsy with Cataplexy, Narcolepsy without Cataplexy, and Secondary Narcolepsy); Product (Central Nervous System (CNS) Stimulants, Sodium Oxybate, and Antidepressants); Distribution Channel (Hospital Pharmacies and Retail Pharmacies) and Geography
Narcolepsy Market Market Scope • The global narcolepsy market accounted to US$ 2,026.8 Mn in 2018 and is expected to grow at a CAGR of 9.5% during the forecast period 2019 – 2027, to account to US$ 4,537.9 Mn by 2027. • The Asia Pacific narcolepsy market is expected to grow at highest rate during the forecast period owing higher number of research & development and increasing investments on sleep related neurological disorders. In addition, emergence of new local players with competitive drug portfolio are expected to fuel the market growth in Asia Pacific region.
Narcolepsy Market MarketSegments
Narcolepsy Market Factors Contributing to MarketGrowth • Rising prevalence of sleep related neurological disorders is expected to boost the market growth over the years • Increasing Awareness Regarding Neurological Disorders • The relationship between public health and neurology was not been adequately explored until recent years. The burden of neurological disorders have increased significantly across the world. These disorders are estimated to affect over a billion population worldwide, according to the World Health Organization by 2016. Neurological disorders are commonly found among all the age groups, in all geographic populations.
Narcolepsy Market Strategic Insights Strategic acquisition and product launches were observed as the most adopted strategy in global narcolepsy industry. Few of the recent product launch and acquisitions are listed below: 2018: Jazz Pharmaceuticals announced FDA approval of Xyrem (sodium oxybate) for the treatment of cataplexy or excessive daytime sleepiness in pediatric narcolepsy patients 2019: Takeda Pharmaceutical Company Limited acquired Shire plc to expand its geographic footprint and leading position in Japan and the U.S. 2018: Jazz Pharmaceuticals announced FDA acceptance of supplemental new drug application for Xyrem (sodium oxybate) to treat cataplexy and excessive daytime sleepiness in pediatric narcolepsy patients For more details, get sample PDF copy: https://www.theinsightpartners.com/sample/TIPRE00003326/
Narcolepsy Market LeadingPlayers • Bioprojet • Teva Pharmaceutical Industries Ltd. • Jazz Pharmaceuticals, Inc. • Graymark Healthcare, Inc. • Arena Pharmaceuticals, Inc. • Shire (Acquired by Takeda) • Ligand Pharmaceuticals, Inc. • Novartis AG • Mylan N.V. • Shionogi Inc.
“ A report titled “Narcolepsy Market - Opportunities and Forecasts, 2018 – 2027 ” has been recently published by The Insight Partners. The report makes close observations of pipeline structure for end-to-end market around the world. It makes an in-depth analysis of current trends, drivers, and restraining factors that affect financial ratios relevant to the industry. Company profiles for key vendors in business builds a comprehensive picture of profitable opportunities from stakeholder’s perspective. ” To know more about the Narcolepsy Market - Opportunities and Forecasts, 2018– 2027report: https://www.theinsightpartners.com/reports/narcolepsy-market Follow uson ThankYou